Clinical trials found that lopinavir/ritonavir had a poor effect on COVID-19, while others, such as arbidol [27, 29], remdesivir [51–54], favipiravir [59], IFN-α2b [100], convalescent plasma [119, 120], corticosteroids [122, 123] and tocilizumab [125–127], had different and even opposite results, which can be further validated by experimental evaluation and clinical experience. Here, IFNA2 is linked to COVID-19.